UA84692C2 - Фармацевтическая композиция, содержащая арипипразол и ингибитор повторного усвоения серотонина, и ее использование для лечения расстройств настоения - Google Patents

Фармацевтическая композиция, содержащая арипипразол и ингибитор повторного усвоения серотонина, и ее использование для лечения расстройств настоения

Info

Publication number
UA84692C2
UA84692C2 UAA200506361A UA2005006361A UA84692C2 UA 84692 C2 UA84692 C2 UA 84692C2 UA A200506361 A UAA200506361 A UA A200506361A UA 2005006361 A UA2005006361 A UA 2005006361A UA 84692 C2 UA84692 C2 UA 84692C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
reuptake inhibitor
serotonin reuptake
aripiprazole
mood disorders
Prior art date
Application number
UAA200506361A
Other languages
English (en)
Ukrainian (uk)
Inventor
Тецуро Кикуки
Таро Ивамото
Цуёши Хиросе
Original Assignee
Оцука Фармасьютикел Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41212155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA84692(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Оцука Фармасьютикел Ко., Лтд. filed Critical Оцука Фармасьютикел Ко., Лтд.
Publication of UA84692C2 publication Critical patent/UA84692C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Фармацевтическая композиция в соответствии с изобретением содержит (1) производное карбостирола и (2) ингибитор повторного усвоения серотонина в фармацевтически приемлемом носителе. При этом производное карбостирила являет собой арипипразол или его метаболит, который является стабилизатором допамин-серотониновой системы. Ингибитор повторного усвоения серотонина выбран из группы, которая содержит флуоксетин, дулоксетин, венлафаксин, милнаципрам, циталопрам, флувоксамин, пароксетин, сертралин, эсциталопрам. Фармацевтическая композиция в соответствии с изобретением пригодна для лечения расстройств настроения, в частности депрессий или тяжелых депрессивных состояний.
UAA200506361A 2002-12-27 2003-12-25 Фармацевтическая композиция, содержащая арипипразол и ингибитор повторного усвоения серотонина, и ее использование для лечения расстройств настоения UA84692C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002379003 2002-12-27

Publications (1)

Publication Number Publication Date
UA84692C2 true UA84692C2 (ru) 2008-11-25

Family

ID=41212155

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200506361A UA84692C2 (ru) 2002-12-27 2003-12-25 Фармацевтическая композиция, содержащая арипипразол и ингибитор повторного усвоения серотонина, и ее использование для лечения расстройств настоения

Country Status (9)

Country Link
US (1) US8759350B2 (ru)
CN (1) CN101879166B (ru)
AR (2) AR042806A1 (ru)
CA (1) CA2716966C (ru)
GE (2) GEP20104888B (ru)
MY (1) MY139551A (ru)
SG (1) SG154337A1 (ru)
TW (2) TWI315669B (ru)
UA (1) UA84692C2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
AU2005302589B2 (en) * 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
US8865937B2 (en) * 2009-11-06 2014-10-21 Mahendra G. Dedhiya Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
EP2536688A4 (en) * 2010-01-14 2014-04-02 Pf Medicament STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
WO2013036403A1 (en) * 2011-09-06 2013-03-14 Curna, Inc. TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES
US20160375016A1 (en) * 2013-06-24 2016-12-29 The Johns Hopkins University Methods for reducing anxiety and impulsivity in subjects initiating treatment with serotonin reuptake inhibitors
EP3294337A1 (en) * 2015-05-13 2018-03-21 A.Carlsson Research AB Treatment of debilitating fatigue

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310524A (en) * 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5591884A (en) * 1989-05-31 1997-01-07 Abbott Laboratories Dopamine agonists
US5500343A (en) * 1990-02-07 1996-03-19 Board Of Regents, The University Of Texas System Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5663167A (en) 1992-12-09 1997-09-02 The United States Of America As Represented By The Department Of Health And Human Services Antipsychotic composition and method of treatment
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
ZA948357B (en) 1994-06-16 1996-04-24 Lilly Co Eli Potentiation of drug response
NZ325036A (en) * 1995-12-22 2001-06-29 Lilly Co Eli Method for treating depression
BR9708254A (pt) * 1996-03-25 1999-08-03 Lilly Co Eli Método para o tratamento da dor
AU2587297A (en) 1996-03-25 1997-10-17 Eli Lilly And Company Method for treating pain
US6159963A (en) * 1996-03-29 2000-12-12 Eli Lilly And Company Method for treating substance abuse
IL121076A (en) 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
GB9801538D0 (en) * 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
EP2338482A3 (en) * 1998-04-14 2011-12-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
BR9909559A (pt) 1998-05-08 2000-12-19 Upjohn Co Novas combinações de drogas
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
AU3891299A (en) 1998-05-21 1999-12-06 Eli Lilly And Company Combination therapy for treatment of depression
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
PL344331A1 (en) 1998-05-22 2001-11-05 Lilly Co Eli Combination therapy for treatment of refractory depression
SK17492000A3 (sk) 1998-05-29 2002-04-04 Eli Lilly And Company Liek na liečenie bipolárnych porúch a farmaceutický prostriedok
US20030027817A1 (en) * 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
US6348455B1 (en) * 1998-11-23 2002-02-19 Sepracor Inc. Desmetylolanzapine compositions and methods
CA2352611A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
AU757870B2 (en) * 1998-11-23 2003-03-06 Sepracor, Inc. Pharmaceutical compositions containing olanzapine-N-oxide
JP2003525865A (ja) * 1999-03-18 2003-09-02 チルドレンズ・ホスピタル・リサーチ・ファウンデイション 非定型抗精神病薬の投与による神経性過食症および関連摂食障害の治療方法
AU4062900A (en) 1999-04-06 2000-10-23 Sepracor, Inc. Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US6599532B2 (en) 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6322503B1 (en) * 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
DE10018834A1 (de) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
CA2364211A1 (en) 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
EP1353675A2 (en) 2001-01-02 2003-10-22 PHARMACIA &amp; UPJOHN COMPANY New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
JP4175113B2 (ja) 2001-03-14 2008-11-05 小野薬品工業株式会社 Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤
EP1379494B1 (en) 2001-04-19 2010-03-10 Warner-Lambert Company LLC Fused bicyclic or tricyclic amino acids
CA2445528A1 (en) * 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US6582737B2 (en) * 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
JP2006505489A (ja) 2002-02-08 2006-02-16 アボット・ラボラトリーズ 精神分裂病の治療のための併用療法
EP1336406A1 (en) * 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
WO2003101492A2 (en) 2002-05-30 2003-12-11 Neurosearch A/S Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
CA2494109A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
EP1556024A4 (en) 2002-10-25 2007-01-17 Collegium Pharmaceutical Inc INTERMITTENT LIBERATION COMPOSITIONS OF MILNACIPRANE
EP1667686A1 (en) 2003-09-09 2006-06-14 Pfizer Products Inc. Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
US20050250803A1 (en) 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY

Also Published As

Publication number Publication date
CA2716966C (en) 2012-12-18
CN101879166A (zh) 2010-11-10
SG154337A1 (en) 2009-08-28
MY139551A (en) 2009-10-30
CN101879166B (zh) 2014-03-19
US20060154938A1 (en) 2006-07-13
GEP20104888B (en) 2010-02-10
GEP20074225B (en) 2007-10-25
TW200940058A (en) 2009-10-01
US8759350B2 (en) 2014-06-24
TWI315669B (en) 2009-10-11
AR042806A1 (es) 2005-07-06
CA2716966A1 (en) 2004-07-22
TW200507846A (en) 2005-03-01
AR098599A2 (es) 2016-06-01
TWI359661B (en) 2012-03-11

Similar Documents

Publication Publication Date Title
MY152919A (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
MY134110A (en) Combinations of reboxetine and neuroleptic agents
MY133238A (en) Monoamine reuptake inhibitors for treatment for cns disorders
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
WO2004010932A3 (en) Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
DE60200492D1 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
BR0200155A (pt) Tratamento combinado para depressão
NZ615591A (en) Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder
WO2004047830A3 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
NO20100333L (no) Behandling av nevrotiske forstyrrelser
AR098599A2 (es) Procedimiento de utilización de una composición farmacéutica que comprende derivados de carboestirilo e inhibidores de la reabsorción de serotonina para preparar un medicamento para el tratamiento de trastornos del animo
BR0306147A (pt) Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
WO2004100939B1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
AR045423A1 (es) Combinaciones de analiticos y antidepresivos
RS51669B (en) NEW DRUG COMBINATIONS AS ANTIDEPRESSIVE
AR056056A1 (es) Asociacion entre la agomelatina y un inhibidor de la recaptacion de la noradrenalina y las composiciones farmaceuticas que las contienen
MXPA06002778A (es) Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
SE9803155D0 (sv) A new composition
Koran Sertraline reduced patient dropout rates and acute exacerbation of symptoms in obsessive compulsive disorder
UY28401A1 (es) Metabolito
TW200626129A (en) Combinations of N-(indolecarbonyl-)piperazine derivatives and serotonin reuptake inhibitors